Cardiovascular Disease in Bladder Cancer Survivors

Share Button

How can you reduce cardiovascular disease in bladder cancer survivors? By living a heart-healthy lifestyle through nutrition, supplementation, and lifestyle therapies.

There is growing research showing that bladder cancer survivors experience higher rates of cardiovascular disease (CVD) than people without a cancer history.

The research below indicates that bladder cancer survivors — like other cancer survivors — have a significantly higher risk of cardiovascular disease than people without a cancer history. This increased risk persists long after cancer treatment and involves multiple cardiovascular outcomes, including CHD, stroke, and heart failure.

Shared risk factors, treatment-related cardiotoxicity, and cancer-related biological changes all appear to play roles. These findings underscore the importance of integrated survivorship care that addresses heart health alongside cancer monitoring.

I have posted the video below because it explains the problem of cardiovascular disease in bladder cancer survivors, and it explains what to do about it. 



I am a long-term cancer survivor of an incurable blood cancer called multiple myeloma. I was diagnosed with chemotherapy-induced cardiomyopathy in late 2015, fully 15 years after my oncologist prescribed cardiotoxic chemotherapy to me.

The cardio-oncologist prescribed a common heart medication called metoprolol. I think bladder cancer survivors may benefit from conventional heart therapies. My purpose in writing this blog is not to condemn conventional heart therapy but rather to promote heart-healthy nutrition, supplementation, and lifestyle.

However, I reacted to the medication and discontinued taking it. I researched evidence-based, heart-healthy therapies that I could pursue on my own, such as exercise, CoQ10, curcumin, omega-3 fatty acids, etc.

Annual echocardiograms over the years have indicated the other heart damage issues below.

I was able to lower my blood pressure, increase my ejection fraction, and stabilize my heart health. I have been able to live without conventional heart medication since 2015.

Again, conventional cardiology should be a part of your long-term survivor plan. I am just saying that evidence-based non-conventional heart health should be included too.

Scroll down the page, post a question or a comment if you’d like to learn more about non-conventional heart health therapies.

Good luck,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Cardiovascular disease burden in patients with urological cancers: The new discipline of uro-cardio-oncology

Abstract

Cancer remains a major cause of mortality worldwide, and urological cancers are the most common cancers among men. Several therapeutic agents have been used to treat urological cancer, leading to improved survival for patients. However, this has been accompanied by an increase in the frequency of survivors with cardiovascular complications caused by anticancer medications.

Here, we propose the novel discipline of uro-cardio-oncology, an evolving subspecialty focused on the complex interactions between cardiovascular disease and urological cancer. In this comprehensive review, we discuss the various cardiovascular toxicities induced by different classes of antineoplastic agents used to treat urological cancers, including androgen deprivation therapy, vascular endothelial growth factor receptor tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics.

In addition, we discuss possible mechanisms underlying the cardiovascular toxicity associated with anticancer therapy and outline strategies for the surveillance, diagnosis, and effective management of cardiovascular complications. Finally, we provide an analysis of future perspectives in this emerging specialty, identifying areas in need of further research…

CONCLUSIONS

There is an important relationship between cardiovascular disease and anticancer therapy. This review can serve as a foundation for a future consensus definition of uro-cardio-oncology. Several medication classes such as

  • GnRH agonists,
  • VEGFR-TKIs,
  • ICIs, and
  • chemotherapeutics

can cause cardiovascular complications. Gaining a comprehensive understanding of the underlying mechanisms involved will facilitate the identification of innovative therapeutic targets for cardiovascular complications. Individualized surveillance and management plans are necessary for patients with urological cancer receiving anticancer treatment. The establishment of multidisciplinary uro-cardio-oncology teams is crucial for improving patient outcomes.

cardiovascular disease in bladder cancer survivors cardiovascular disease in bladder cancer survivors

 

Leave a Comment: